Neurodegeneration in tauopathies and synucleinopathies by Foguem, Clovis & Kamsu-Foguem, Bernard
Short communication
Neurodegeneration in tauopathies and
synucleinopathies
C. Foguem a,b, B. Kamsu-Foguem c,*
aEpernay Hospital Centre, 137, rue de l’Hoˆpital Auban-Moe¨t, BP 137, 51205 Epernay, France
bCenter for Food and Taste sciences (CSGA), UMR 6265 CNRS, UMR 1324 INRA, University of Burgundy, 9E,
boulevard Jeanne-d’Arc, 21000 Dijon, France
c Laboratory of Production Engineering (LGP), EA 1905, ENIT-INPT University of Toulouse, 47, avenue d’Azereix,
BP 1629, 65016 Tarbes cedex, France
r e v u e n e u r o l o g i q u e 1 7 2 ( 2 0 1 6 ) 7 0 9 – 7 1 4
i n f o a r t i c l e
Article history:
Received 30 December 2015
Accepted 25 May 2016
Available online 22 June 2016
Keywords:
Neurodegenerative diseases
Alzheimer’s disease
Parkinson’s disease
Dementia with Lewy bodies
Dementia
a b s t r a c t
While increasing life expectancy is a major achievement, the global aging of societies raises
a number of medical issues, such as the development of age-related disorders, including
neurodegenerative diseases. The three main disease groups constituting the majority of
neurodegenerative diseases are tauopathies, alpha-synucleinopathies and diseases due to
repetitions of glutamine (including Huntington’s disease). In each neurodegenerative
disease, the accumulation of one or more aggregated proteins has been identified as the
molecular signature of the disease (as seen, for example, in Alzheimer’s disease, Parkinson’s
disease, dementia with Lewy bodies, amyotrophic lateral sclerosis and frontotemporal
dementia). The etiology of neurodegenerative diseases is often multifactorial, and the
known risk factors include, in addition to genetic polymorphisms and age, some other
possible causes, such as certain immune and metabolic conditions, endocrine pathologies,
gender, socioeconomic or professional status, oxidative stress or inflammation, vitamin
deficiencies and environmental factors (chemical exposure, metals). However, innovative
strategies to elaborate suitable diagnostic and therapeutic approaches (aiming to at least
delay or possibly even reverse disease progression) require further knowledge of the genetic
and adaptive immunological characteristics of neurodegenerative diseases.
# 2016 Elsevier Masson SAS. All rights reserved.
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In every neurodegenerative disease, the accumulation of one
or more aggregated proteins has been identified as the
molecular signature of the disease [as seen in, for example,
Alzheimer’s disease (AD), Parkinson’s disease (PD), dementia
with Lewy bodies (DLB), amyotrophic lateral sclerosis (ALS)* Corresponding author.
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0035-3787/# 2016 Elsevier Masson SAS. All rights reserved.and frontotemporal dementia (FTD)] [1]. The proteins that
accumulate in the central nervous system of patients with
such diseases were initially identified by the purification of
polypeptides from the brains of affected humans and
animals [2]. It is currently assumed that the basic mechanism
of cell death in degenerative diseases is related to a rather
restricted number of processes in which oxidative stress.
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aggregation, which may be signs of differential clinical
expressions [3].
The identification of specific mutations in certain genes is
oriented towards certain proteins and pathways currently
considered critical in the pathogenesis of the most prominent
neurodegenerative diseases (Table 1). These include muta-
tions of precursor proteins: amyloid beta (Ab or Abeta) causes
AD; alpha-synuclein leads to PD or DLB; and microtubule-
associated protein tau (MAPT) causes FTD with parkinsonism.
These aberrant misfolded proteins occurred initially in
specific brain areas and were secondarily found in widerTable 1 – Intraneuronal filamentous inclusions in neurodegen
Disease Filamentous inclusions 
Alzheimer’s disease Neurofibrillary tangles (lesion
Pick’s disease (type of frontotemporal
dementia)
Pick bodies 
FTDP-17 Neurofibrillary lesions, glial fi
Progressive supranuclear palsy (PSP) Neurofibrillary lesions, glial fi
Corticobasal degeneration (CBD) Neurofibrillary lesions, glial fi
Parkinson’s disease Lewy bodies and neurites 
Dementia with Lewy bodies (DLB) Lewy bodies and neurites 
Multiple system atrophy (MSA) Neuronal and glial inclusions
Huntington’s disease Intranuclear inclusions, dystr
Spinocerebellar ataxia type 1 (SCA1) Intranuclear inclusions 
Spinocerebellar ataxia type 3 (SCA3) Intranuclear inclusions 
Spinocerebellar ataxia type 7 (SCA7) Intranuclear inclusions 
DRPLA, or Naito–Oyanagi disease Intranuclear inclusions 
Spinal and bulbar muscular
atrophy (SBMA)
Intranuclear inclusions 
FTDP-17: frontotemporal dementia and parkinsonism linked to chromos
atrophy.
Fig. 1 – Brain anatomical locations of primary macro- and micr
particular neurodegenerative diseases. PrP: prion protein; FTD:
Lewy body dementia (including Parkinson disease dementia, P
disease; HD: Huntington’s disease; ALS: amyotrophic lateral scareas of the brain as the neurodegenerative disease symptoms
worsened or the disease entered its later stages (Figs. 1 and 2)
[4,5].
Furthermore, the prion concept explains how a disease can
manifest as hereditary, sporadic or infectious. In addition, the
common feature of prion diseases (sporadic, dominant
inheritance, acquired through infection) is that they involve
aberrant metabolism of prion protein. An important feature
that distinguishes prion viruses is the two isoforms of prion
protein (PrP) encoded by a chromosomal gene. In humans, the
PrP gene is designated PRNP and is located in the short arm of
chromosome 20.erative diseases.
Main component
s) Tau protein
Tau protein
brillary lesions Tau protein
brillary lesions Tau protein
brillary lesions Tau protein
Alpha-synuclein
Alpha-synuclein
 Alpha-synuclein
ophic neurites PolyQ repeat expansion in huntingtin protein
PolyQ repeat expansion in ataxia type 1 protein
PolyQ repeat expansion in ataxia type 3 protein
PolyQ repeat expansion in ataxia type 7 protein
PolyQ repeat expansion in ataxia type 1 protein
PolyQ repeat expansion in androgen receptor
ome 17; PolyQ: polyglutamine; DRPLA: dentatorubral-pallidoluysian
oscopic changes (misfolded proteins) are characteristic of
 frontotemporal dementia; AD: Alzheimer’s disease; LBD:
DD and dementia with Lewy bodies, DLB); PD: Parkinson’s
lerosis. From Bertram and Tanzi [4].
Fig. 2 – Sequential topographical dissemination of non-prion proteins in neurodegenerative diseases. Pathology is first
detected in areas shown in darker colours and then in regions shown in lighter colours. (a and b) In Alzheimer’s disease
(AD), tau aggregates develop initially in the locus ceruleus (LC), then in transentorhinal and entorhinal regions, and finally
in the hippocampal formation and wide areas of neocortex (NC). (c and d) In contrast to tau pathology, amyloid-b deposits
in AD are first seen in NC and then in allocortical, diencephalic and basal ganglia structures (caudal direction), brainstem,
and sometimes cerebellum (CB). (e and f) Progression of a-synuclein immunoreactive Lewy body/neurite pathology in
Parkinson’s disease follows an ascending pattern from brainstem to telencephalon. Earliest lesions are in the olfactory bulb
(OB) and dorsal motor nucleus of the vagus nerve (DMX) in the medulla oblongata. (g and h) In amyotrophic lateral sclerosis
with a low burden of TAR DNA-binding protein 43 (TDP43) pathology, TDP43 inclusions are seen initially in the agranular
motor cortex (AGN), brainstem motor nuclei of cranial nerves XII–X, VII and V, and a-motor neurons in the spinal cord. AC:
allocortex; BFB: basal forebrain; BN: brainstem nuclei; BSM: brainstem somatomotor nuclei; ENT: entorhinal cortex; MTC:
mesiotemporal cortex; PFN: prefrontal neocortex; SC9: spinal cord gray-matter lamina IX; SN: substantia nigra; TH:
thalamus. Reprinted from Brettschneider et al. [5] and Braak et al. [16].
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neurodegenerative diseases
The three main disease groups constituting the majority of
neurodegenerative diseases are the tauopathies, alpha-synu-
cleinopathies and diseases due to repetitions of glutamine
(including Huntington’s disease; Table 1).
Tauopathies (including AD, FTD and progressive supranu-
clear palsy) and alpha-synucleinopathies [comprising mainly
PD, DLB and multiple system atrophy (MSA)] represent the
majority of late-onset neurodegenerative diseases in humans.
Amyloidopathies, tauopathies and synucleinopathies share
common pathological features in terms of structural, aggre-
gatory and spreading properties (the pathophysiological
molecular mechanisms leading to cellular toxicity) [6]. The
factors that generate tauopathy and its extension within areas
of the brain are not well known; amyloid precursor protein
(APP) gene dysfunction is the best candidate so far, as revealed
by genetic studies [7]. The development of intracellularfilamentous inclusions could bring a risk of acute or chronic
toxicity, leading to injury or damage to brain cells [8].
3. Etiology of neurodegenerative diseases
Another feature observed in the most common neurodege-
nerative diseases is the dichotomy between familial (rare) and
non-familial forms (most common; Table 2). These are also
frequently described as ‘sporadic’ or ‘idiopathic’, although
there is a growing body of evidence suggesting that a large
proportion of these cases are also strongly influenced by
genetic factors. The genetics behind these diseases has been
labeled ‘complex’, in contrast to the classical Mendelian
genetics dubbed ‘simplex’ (single mode or single inheritance),
due to the involvement of numerous genes that are likely to
have complex interactions with each other and with non-
genetic variables as well (Fig. 3). The genetics considered
complex would be governed by common deoxyribonucleic
Table 2 – Etiological frequency (sporadic, genetic and
infectious) of neurodegenerative pathologies.
Diseases Etiological frequency (%)
Sporadic Genetic Infectious
Prion disease 85 > 10 < 1
Alzheimer’s disease 90 10
Parkinson’s disease 95 < 5
Frontotemporal dementia 90 10
Pick’s disease 95 < 5
Progressive supranuclear
palsy (PSP)
95 < 5
Amyotrophic lateral
sclerosis (ALS)
90 10
Huntington’s disease (HD) 100
Spinocerebellar ataxia (SCA) 100
r e v u e n e u r o l o g i q u e 1 7 2 ( 2 0 1 6 ) 7 0 9 – 7 1 4712acid (DNA) variants, such as single nucleotide polymorphisms,
which significantly increase the risk of disease, yet are
insufficient to effectively cause a disorder or specific disease.
Innovative strategies to elaborate suitable therapeutic
approaches (aiming to at least delay and possibly even reverse
disease progression) require knowledge of the genetic and
adaptive immunological characteristics of these neurodegene-
rative diseases. Genetic evidence supports the idea that multiple
neurodegenerative pathways lead to mild cognitive impairment
and that the eventual conversion to dementia, principally of
the AD subtype, is essentially due to the AD pathway(s) [9].
The etiology of neurodegenerative diseases is often
multifactorial, although these chronic diseases share two
main characteristics:
 neuronal loss in motor, sensory or cognitive systems,
generating mental and motor decline;
 a strong association between metabolic changes and
neurodegeneration (for example, disruption of the link
between the peripheral organs governing energy metabo-
lism and the cognitive and neural systems) [10].
The known risk factors for neurodegenerative diseases
include, in addition to genetic polymorphisms and age, otherCOMM ON NEUR ODE GENER ATIVE  DISEASES  IN 
Synuclei n , Tau  and  Glutamine  Dysfunction s
Synuclei n , Tau  and  Glutamine  Aggregation 
Neurodegene rative  Disea ses
?
Genetic Factors
Alpha -S ynuclei n Mutations  Tau Mutations
Repetition s of glu tamine   
No
Professional soci o-eco 
Environmen tal  Factor s
Inflammation,  vitamin  
Fig. 3 – Spectrum of risk predisposing to common neurodegene
predisposition from non-genetic factors.possible causes such as certain endocrine pathologies, gender,
socioeconomic or professional status, oxidative stress or
inflammation, vitamin deficiencies [especially of vitamin B9
(folic acid) and vitamin B12], immune and metabolic condi-
tions, and environmental factors (such as chemical exposure
and heavy metals; Fig. 3). Indeed, some studies have revealed
correlations between chronic pesticide exposures in occupa-
tional settings and the development of neurological disorders
[11]. In addition, epigenetic regulation of gene expression and
environmental modulation are factors that may play a key role
in the onset and course of common neurological conditions,
including AD, PD, Huntington’s disease (HD) and multiple
sclerosis (MS) [12]. The immune system also has an important
role in neurodegenerative disorders: while there are undoubt-
edly maladaptive components of neural inflammation that
serve to spread a neurotoxic environment that can encourage
neuropathogenic lesions, there is also the opportunity to use
adaptive and beneficial microglial/monocyte phenotypes to
enable beneficial neuroimmune responses in some neurode-
generative diseases (such as AD and PD) [13].
4. Discussion
The degenerative processes in brain cells are considered
‘primary’ when no causal factor can be identified, and
‘secondary’ when triggering factors are demonstrated (inflam-
matory factors, or toxic, metabolic or traumatic events). These
triggering factors of neurodegenerative pathologies are still
mostly unknown, making a timely and accurate diagnosis
difficult to achieve during antemortem assessment of these
diseases [1]. Although in certain cases, the diagnosis made by a
clinician can be confirmed postmortem by pathological
examination, it is generally accepted that diagnostic errors
may be identified from the patient’s postmortem anatomical
pathological findings. In many situations, there are difficulties
in diagnosis, as some neurodegenerative diseases have many
signs and symptoms in common. The diagnosis of DLB is
particularly difficult as some of its symptoms can be found in
other neurodegenerative diseases, such as PD and AD, thereby
often leading to its misdiagnosis.THE  ELDER LY: KE Y POI NTS
s
n-Genetic Factors
nomic or  professional  status   Individual variables  (gender  and  age)
 (chemi cal e xpo sure, me tals,  etc. )
deficienci es, immune  and  metabolic  condition s
rative diseases. This regrouping distinguishes genetic
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affecting 20 to 25 million people worldwide, and is the fourth
leading cause of death in industrialized countries. Its
prevalence rate is around 7% in those aged  65, with the
doubling of risk for every 5 years after age 65. Some studies of
AD suggest that the gene encoding spondin 1 (SPON1) may be
associated with the differential rate of cognitive decline in AD
patients [14,15].
PD is the second most common neurodegenerative disease
associated with intraneuronal filamentous inclusions made
up of aggregated alpha-synuclein in Lewy bodies and
dystrophic neurites. It affects between six and seven million
people around the world. Some rare familial forms of PD are
caused by mutations of the gene for alpha-synuclein [8].
DLB is the second most common neurodegenerative
dementia after AD, and the second most common synuclei-
nopathy after PD, FTD represents 5–10% of all dementias,
including Pick’s disease. These disorders are related to
mutations of the tau gene in familial FTD and parkinsonism
linked to chromosome 17 (FTDP-17). For most of these
diseases, the definitive diagnosis can only be made by
pathological examination of brain tissue.
The primary neurodegenerative diseases that lead to a
dementia syndrome have a number of common characteris-
tics and constitute a consistent set of features:
 the neurodegenerative process is slow and can take 20 years
before the onset of its first clinical manifestations, making it
difficult to precisely date the beginning of the disease or
even the start of the first clinical signs;
 the brain damage is irreversible, so the clinical signs persist
over time;
 the symptomatology and all clinical signs of the dementia
are important;
 the course of the illness trends towards a loss of indepen-
dence.
5. Conclusion
There is accumulating evidence that most neurodegenerative
diseases are due to deposits of aberrantly misfolded and
aggregated brain proteins. Pathologies with a primary degene-
rative process mainly include AD, PD, DLB, ALS, HD, FTD and
prion diseases. AD is characterized by degeneration of neuronal
cells due to filamentous neuronal inclusions, comprising the
microtubule-associated protein tau in a hyperphosphorylated
state; tau is the key constituent of neurofibrillary tangles and
has a synergistic relationship with APP dysfunction.
The pathological accumulation of alpha-synuclein and
Lewy bodies in the brains of PD patients (as postulated by
Braak et al.) [16] could lead to the development of a predictable
six-stage sequence of lesions, based on a stepwise patholo-
gical progression starting from the medullary nuclei and
olfactory cortex. Implementation of such a staging strategy to
categorize the degree of pathology in PD might then influence
the patient’s final diagnosis [16,17]. However, it has been
shown that, in certain rare cases, there is no relationship
between the Braak stage and clinical severity of PD [18].The clinical syndrome of DLB seems to be directly related to
Lewy body pathology and is often inversely related to the
pathological lesions associated with AD. Thus, DLB neuropa-
thological criteria could be useful for making a precise
diagnosis. In particular, a visual semi-quantitative analysis
could be used to differentiate DLB from PD in the brain: lesions
in the latter have a distribution predominantly in the
brainstem whereas, in the former, the distribution and
frequency of Lewy bodies are likely be diffused throughout
the neocortex. Imaging of the dopaminergic system using
123I-fluoropropyl-2-beta-carbomethoxy-3-beta(4-iodophenyl)-
nortropane (FP-CIT) single-photon emission computed tomo-
graphy (SPECT) may represent an accurate method for
differentiating DLB from other dementia syndromes [19].
Filamentous inclusions of tau protein have been identified
in the brains of patients with FTD, and especially Pick’s
disease. This has been revealed to be due to mutations in the
tau gene in familial forms of FTD, thus providing a direct link
between tau protein dysfunction and dementia severity [8].
Finally, in MSA, which is less common than the other
neurodegenerative pathologies and often confused with PD
at the clinical level, the accumulation of misfolded alpha-
synuclein has been described, as well as multiple forms of
neural degeneration similar to those found in PD and DLB
[20].
In future, the development of strategies to elaborate new
potentially therapeutic approaches and of further research
aimed at the discovery of novel drugs for neurodegenerative
diseases will require greater knowledge of the innate and
adaptive immunological aspects of neurodegenerative disea-
ses (such as those found in PD, AD and ALS) [21,22].
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